Q4 2024 Holdings
Filed 2025-02-14 | 48 holdings | $1.8B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Moonlake Immunotherapeutics(MLTX) | CLASS A ORD | 61559X104 | $460.0M | 8,494,151 | 25.3% |
| Praxis Precision Medicines I(PRAX) | COM NEW | 74006W207 | $130.3M | 1,693,219 | 7.2% |
| Janux Therapeutics Inc(JANX) | COM | 47103J105 | $112.4M | 2,100,000 | 6.2% |
| Arcellx Inc(ACLX) | COMMON STOCK | 03940C100 | $99.7M | 1,300,000 | 5.5% |
| Edgewise Therapeutics Inc(EWTX) | COM | 28036F105 | $91.0M | 3,406,534 | 5.0% |
| Newamsterdam Pharma Company(NAMS) | ORDINARY SHARES | N62509109 | $83.5M | 3,250,000 | 4.6% |
| Eyepoint Pharmaceuticals Inc(EYPT) | COM NEW | 30233G209 | $62.0M | 8,325,000 | 3.4% |
| Rapport Therapeutics Inc(RAPP) | COM | 75383L102 | $52.2M | 2,940,921 | 2.9% |
| Crinetics Pharmaceuticals in(CRNX) | COM | 22663K107 | $51.1M | 1,000,000 | 2.8% |
| Insmed Inc(INSM) | COM PAR $.01 | 457669307 | $44.9M | 650,000 | 2.5% |
| Bridgebio Pharma Inc(BBIO) | COM | 10806X102 | $43.9M | 1,600,000 | 2.4% |
| Centessa Pharmaceuticals PLC(CNTA) | SPONSORED ADS | 152309100 | $42.9M | 2,561,600 | 2.4% |
| Bright Minds Biosciences Inc(DRUG) | COM NEW | 10919W405 | $38.2M | 1,059,331 | 2.1% |
| Vaxcyte Inc(PCVX) | COM | 92243G108 | $34.8M | 425,000 | 1.9% |
| Merus N V | COM | N5749R100 | $31.1M | 740,000 | 1.7% |
| Helix Acquisition Corp II | CL A ORD SHS | G4444H101 | $30.5M | 2,909,000 | 1.7% |
| Avidity Biosciences Inc(RNA) | COM | 05370A108 | $30.5M | 1,050,000 | 1.7% |
| Pharvaris N V(PHVS) | COM | N69605108 | $28.1M | 1,466,460 | 1.5% |
| Corbus Pharmaceuticals Hldgs(CRBP) | COM NEW | 21833P301 | $28.0M | 2,375,000 | 1.5% |
| Tarsus Pharmaceuticals Inc(TARS) | COM | 87650L103 | $27.7M | 500,000 | 1.5% |
| Axsome Therapeutics Inc(AXSM) | COM | 05464T104 | $27.5M | 325,000 | 1.5% |
| Arcutis Biotherapeutics Inc(ARQT) | COM | 03969K108 | $25.4M | 1,825,000 | 1.4% |
| Rhythm Pharmaceuticals Inc(RYTM) | COM | 76243J105 | $22.4M | 400,000 | 1.2% |
| CG Oncology Inc(CGON) | COM | 156944100 | $22.2M | 775,000 | 1.2% |
| Cargo Therapeutics Inc(CRGX) | COM | 14179K101 | $17.1M | 1,182,563 | 0.9% |
| Alumis Inc(ALMS) | COM | 022307102 | $16.9M | 2,147,396 | 0.9% |
| Onkure Therapeutics Inc(OKUR) | COM CL A | 68277Q105 | $15.8M | 1,837,739 | 0.9% |
| Arrivent Biopharma Inc(AVBP) | COM | 04272N102 | $15.6M | 585,462 | 0.9% |
| Abivax SA(ABVX) | SPONSORED ADS | 00370M103 | $15.6M | 2,130,000 | 0.9% |
| Engene Holdings Inc(ENGN) | COM | 29286M105 | $15.5M | 2,323,595 | 0.8% |
| Bioage Labs Inc(BIOA) | COM | 09077V100 | $15.2M | 2,629,529 | 0.8% |
| Biomea Fusion Inc(BMEA) | COM | 09077A106 | $13.9M | 3,570,872 | 0.8% |
| MBX Biosciences Inc(MBX) | COM | 55287L101 | $12.9M | 700,000 | 0.7% |
| Septerna Inc(SEPN) | COM | 81734D104 | $12.8M | 560,000 | 0.7% |
| Immunitybio Inc(IBRX) | COM | 45256X103 | $7.7M | 3,000,000 | 0.4% |
| Enliven Therapeutics Inc(ELVN) | COM | 29337E102 | $5.6M | 250,000 | 0.3% |
| ARS Pharmaceuticals Inc(SPRY) | COM | 82835W108 | $5.3M | 500,000 | 0.3% |
| Vyne Therapeutics Inc(VYNE) | COM | 92941V308 | $4.7M | 1,394,336 | 0.3% |
| Kala BIO Inc(KALA) | COM NEW | 483119202 | $4.2M | 603,027 | 0.2% |
| GH Research PLC(GHRS) | ORDINARY SHARES | G3855L106 | $4.2M | 593,043 | 0.2% |
| Y-Mabs Therapeutics Inc(YMABUSD) | COM | 984241109 | $3.3M | 425,000 | 0.2% |
| Urogen Pharma LTD(URGN) | COM | M96088105 | $3.2M | 300,000 | 0.2% |
| Omeros Corp(OMER) | COM | 682143102 | $3.0M | 300,000 | 0.2% |
| Stoke Therapeutics Inc(STOK) | COM | 86150R107 | $2.8M | 254,161 | 0.2% |
| Biohaven LTD(BHVN) | COM | G1110E107 | $2.1M | 55,539 | 0.1% |
| Verve Therapeutics Inc | COM | 92539P101 | $2.0M | 350,000 | 0.1% |
| Artiva Biotherapeutics Inc(ARTV) | COM | 04317A107 | $1.0M | 103,633 | 0.1% |
| Rapt Therapeutics Inc(RAPTEUR) | COM | 75382E109 | $316.0K | 200,000 | 0.0% |